SecBot SecBot

APRE

Aprea Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001781983 Biotech & Drug Discovery
$0.5180 −0.02 (−4.43%)
Oct 23 4:00 PM ET · prev $0.5420
Market cap
$6.8M
Nano cap
Consensus
Buy
89% Buy or better · 9 analysts
Median target
🔒 Subscribers only
1 year
−63.0%
from $1.40 · Oct 24
30 days
−33.6%
from $0.7800
52-week range
$0.5180–1.45
at the low
Avg volume 20D
268.1K
Oct 2 spike 862.2K
Short interest
508.8K
≈4.0% of shares · −11.4%
Days to cover
2.5
at average volume
Insider net
+$155.1K
3 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
10
analyzed by SecBot
SecBot read MIXED 3 reports · 90 days
Balance 0 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 1/3 ·Next Earnings date, Nov 10, 2026
Strongest NEUTRAL Aprea Therapeutics reported Q2 2026 results with a net loss of $3.6M ($-0.07/share), widening from a $3.2M…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    3 insiders bought $155.1K at an average $0.8219. No open-market sales. Price is 37% below their cost.

  • InstitutionsMIXED

    Q2 2026: 2 added (0 new), 2 trimmed or exited.

  • AnalystsBULLISH

    8 of 9 rate it Buy or better.

  • Short sellersSTEADY

    Short interest −11.4% to 508.8K shares. 2.5 days to cover, ≈4.0% of shares.

  • TrendDOWNTREND

    27% below its 50-day average. New closing low $0.5180 on Oct 23.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 11.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
RENAISSANCE TECHNOLOGIES LLCDOUBLED105,800$84.9K
GEODE CAPITAL MANAGEMENT, LLCTRIM74,869$60.1K
SUSQUEHANNA INTERNATIONAL GROUP, LLPDOUBLED34,939$28.0K
UBS Group AGNEAR_EXIT3$2.00
GEODE CAPITAL MANAGEMENT, LLCDOUBLED119,131$90.9K
BNP PARIBAS FINANCIAL MARKETSADD39,817$30.4K
MORGAN STANLEYTRIM22,330$17.0K
VANGUARD GROUP INCTRIM58,086$49.5K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

9 analysts
Buy 89% rate it Buy or better
Strong Buy3Buy5Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 14, 2026Ladenburg Thalmann
INITIATE
INITIATEBuy
Aug 13, 2026Wedbush
MAINTAIN
MAINTAINOutperform
May 14, 2026Wedbush
MAINTAIN
MAINTAINOutperform
May 7, 2026Oppenheimer
INITIATE
INITIATEOutperform
Reddit
Recent posts
r/pennystocks Bullish 15d ago
APRE — strong cash position, a small remaining ATM, and a November catalyst
1 upvotes · 0 comments
All social signals and their track records

Insider ledger

Form 4
$155.1K
bought · 3 insiders
$0
sold · 0 insiders
−37.0%
vs their $0.8219 cost
DateInsiderTypeValue
Jun 16, 2026
Seizinger Bernd R.
Director
AWARD3,135 sh
Jun 16, 2026
Seizinger Bernd R.
Director
AWARD12,555 sh
Jun 16, 2026
Peters Richard
Director
AWARD3,135 sh
Jun 16, 2026
Pamukcu Rifat
Director
AWARD3,135 sh
Jun 16, 2026
Pamukcu Rifat
Director
AWARD12,555 sh
Jun 16, 2026
Gruia Gabriela
Director
AWARD12,555 sh
Jun 16, 2026
Duey Marc
Director
AWARD3,135 sh
Jun 16, 2026
Duey Marc
Director
AWARD12,555 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
508,841
shares short
-11.4%
vs prior settlement
2.5
days to cover
≈4.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 5, 2026 Other
Aprea Therapeutics to Present at October Conferences
Company to participate in 2026 Maxim Growth Summit (October 14) and Regional Biotechnology Conferenc
Aug 28, 2026 SEC
Aprea Therapeutics issued a press release on August 28, 2026, announcing an expansion of its intellectual property…
8-K — Impact 2/10
Aug 12, 2026 SEC
Aprea Therapeutics reported Q2 2026 results with a net loss of $3.6M ($-0.07/share), widening from a $3.2M loss in Q2…
PRESS-RELEASE — Impact 5/10
Aug 12, 2026 SEC
Aprea Therapeutics reported Q2 2026 financial results with a net loss of $3.6M ($-0.07/share), widening from a $3.2M…
8-K — Impact 5/10
Jun 30, 2026 Inst.
RENAISSANCE TECHNOLOGIES LLC — DOUBLED
105,800 shares ($84.9K)
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — TRIM
74,869 shares ($60.1K)
Jun 16, 2026 Insider
Seizinger Bernd R. was granted 3,135 shares
Director
Jun 16, 2026 Insider
Seizinger Bernd R. was granted 12,555 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 10, 2026
Earnings date
🔒 Fresh data — subscribers only
Recent
Oct 5, 2026
Press release
Aprea Therapeutics to Present at October Conferences
Company to participate in 2026 Maxim Growth Summit (October 14) and Regional Biotechnology Conference (October 15) Company to participate in 2026…
Sep 21, 2026
Clinical Trial
Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine
Phase Phase 2 — COMPLETED
Sep 10, 2026
Press release
Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
DOYLESTOWN, Pa., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision…
Aug 28, 2026
Press release
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents Company Strengthens Global Intellectual Property…
Aug 12, 2026
Earnings
Aprea Therapeutics Announces Second Quarter 2026 Financial Results
Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances

SecBot reports

10 filings · 2 press releases · 2 bullish · 3 bearish · 5 neutral
All APRE filing & press-release reports (12)